Hikma, Sun Pharma in licensing agreement for Ilumya for the MENA region

Hikma Pharmaceuticals and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma), the world’s fourth largest specialty generic pharmaceutical company, announced today that they have entered into an exclusive licensing and distribution agreement for Ilumya, an innovative biologic product, for the Middle East and North Africa (MENA) region.

ILUMYA™ (tildrakizumab) is a USFDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma will be responsible for product supply. Sun Pharma is eligible for upfront and milestone payments. The term of this agreement is 15 years from first sale with two years automatic renewal periods. This agreement augments our dermatology and biotech-immunology strategy in MENA and adds an innovative biologic product to our psoriasis portfolio.

Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA said, “We are excited to partner with Sun Pharma and bring ILUMYA™ to our patients in MENA. ILUMYA™ is the first innovative monoclonal antibody product we add to our portfolio. As a pharmaceutical company whose mission is to put ‘better health within reach everyday’, this key collaboration strengthens our biotechnology and dermatology portfolio offering a wider array of treatment choices available in the MENA region, and enables us to increase patients’ access to targeted therapies and specialty products.”  

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.